Predictive Biomarkers Market Revenue Report with Forecast to 2031

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Biomarkers Market- (By Indication (Cancer, Neurological Disorder, Cardiovascular Disorder, Immunological Disorder, Others), By End-Use (Diagnostic Centers, Contract Research Organizations (CROs), Academic Research Institutes, Pharma & Biotech Companies, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Predictive Biomarkers Market is expected to grow with a CAGR of 14.27% during a forecast period of 2023-2031.

Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/2003

A predictive biomarker is a measurable indicator that reflects the biological condition or disease state of a specific organ, tissue, or cell. These biomarkers are widely employed across medical diagnostics, safety assessments, and the drug discovery and development process. Based on their function, predictive biomarkers are categorized into diagnostic, prognostic, and predictive types, each playing a critical role in pharmaceutical development and the broader field of biomedical research. Additionally, predictive biomarkers can be classified according to their biological attributes, such as genomics, proteomics, and others.

The growing number of clinical trials is a major driver of revenue growth in this market. Moreover, continuous advancements and innovations in the field are enhancing the utility and precision of predictive biomarkers. These tools are increasingly used to identify patients most likely to benefit from adjuvant therapies, including radiotherapy and chemotherapy. The rising global prevalence of cardiovascular and other chronic diseases further contributes to the expanding demand for predictive biomarkers, thereby propelling market growth.

List of Prominent Players in the Predictive Biomarkers Market:
• Thermo Fisher Scientific Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina Inc.
• Merck KGaA
• Bio-Techne Corporation
• Siemens Healthineers AG
• PerkinElmer, Inc.
• Myriad Genetics, Inc.
• Becton, Dickinson and Company
• Danaher Corporation
• Genomic Health, Inc.
• Pacific Biosciences of California, Inc.
• Others

Market Dynamics:
Drivers-
The increasing utilization of biomarkers in diagnostics is a key factor propelling the growth of the biomarker market. Market expansion is further supported by the growing number of research and development initiatives funded by pharmaceutical and biotechnology companies, alongside the rising global incidence of cancer.

Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/2003

Challenges:
The development and application of predictive biomarkers face several significant challenges. One of the primary obstacles is the complex and time-intensive validation process required to ensure biomarkers meet the necessary standards of accuracy, specificity, and reproducibility across diverse patient populations. Inadequate validation can compromise clinical outcomes by producing false-positive or false-negative results.

Regional Trends:
North America is anticipated to hold a leading share of the global predictive biomarkers market and is expected to exhibit a strong compound annual growth rate in the coming years. This growth is attributed to the high prevalence of chronic diseases, a well-developed healthcare infrastructure, extensive research and development activities, and increasing adoption of personalized therapeutic approaches. The region also benefits from a robust research ecosystem, supported by academic institutions, government initiatives, and private sector investments. In Europe, a well-defined regulatory framework-led by the European Medicines Agency (EMA)-facilitates the development and approval of biomarker-based products, further supporting market expansion across the region.

Recent Developments:
• In Nov 2022, Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, which is a predictive biomarker, was approved by the FDA as the first IHC-based companion diagnostic to find ovarian cancer patients who are suitable for ELAHERE. The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay was made as a measure that can be used to make predictions.
• In Sept 2020, The Thermo Fisher Precision Medicine Science Centre (PMSC) announced new collaborations with AstraZeneca and the University of Nebraska Medical Centre to explore revolutionary clinical biomarker discovery solutions. The new alliances helped the PMSC standardise workflows with pharma and academic partners to streamline biomarker research to clinical implementation, enabling precision medicine potential.

Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/2003

Segmentation of Predictive Biomarkers Market-
By Indication-
• Cancer
• Neurological Disorder
• Cardiovascular Disorder
• Immunological Disorder
• Others
By End-Use-
• Diagnostic Centers
• Contract Research Organizations (CROs)
• Academic Research Institutes
• Pharma & Biotech Companies
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Get more information :@
https://www.insightaceanalytic.com/report/predictive-biomarkers-market/2003

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG

Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace

This release was published on openPR.